These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35331501)

  • 1. Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis.
    Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
    Clin Nutr ESPEN; 2022 Apr; 48():267-274. PubMed ID: 35331501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study.
    Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
    Bone; 2022 Sep; 162():116480. PubMed ID: 35787482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study.
    Tominaga A; Wada K; Kato Y; Nishi H; Terayama Y; Okazaki K
    Osteoporos Int; 2021 Apr; 32(4):653-661. PubMed ID: 32979066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
    Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Hirao M; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Okamura G; Etani Y; Takami K; Goshima A; Nakata K
    Bone; 2020 Nov; 140():115574. PubMed ID: 32777516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
    Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
    Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis.
    Ebina K; Kashii M; Hirao M; Hashimoto J; Noguchi T; Koizumi K; Kitaguchi K; Matsuoka H; Iwahashi T; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2017 Sep; 35(5):571-580. PubMed ID: 27830384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration.
    Kobayakawa T; Miyazaki A; Kanayama Y; Hirano Y; Takahashi J; Suzuki T; Nakamura Y
    Mod Rheumatol; 2023 Jan; 33(1):96-103. PubMed ID: 35234889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
    Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
    J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study.
    Baek KH; Chung YS; Koh JM; Kim IJ; Kim KM; Min YK; Park KD; Dinavahi R; Maddox J; Yang W; Kim S; Lee SJ; Cho H; Lim SK
    Endocrinol Metab (Seoul); 2021 Feb; 36(1):60-69. PubMed ID: 33677928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab.
    Hattori K; Kanayama Y
    Mod Rheumatol; 2024 Feb; ():. PubMed ID: 38300506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study.
    Kobayakawa T; Suzuki T; Nakano M; Saito M; Miyazaki A; Takahashi J; Nakamura Y
    Bone Rep; 2021 Jun; 14():101068. PubMed ID: 33981812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Real-World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study.
    Inose H; Ariga A; Motoyoshi T; Fukushima K; Tomizawa S; Kato T; Takahashi K; Yoshii T; Okawa A
    JBMR Plus; 2022 Jul; 6(7):e10637. PubMed ID: 35866147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Kato Y
    Osteoporos Int; 2021 Oct; 32(10):1999-2009. PubMed ID: 33770201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study.
    Ebina K; Nagayama Y; Kashii M; Tsuboi H; Okamura G; Miyama A; Etani Y; Noguchi T; Hirao M; Miura T; Fukuda Y; Kurihara T; Nakata K; Okada S
    Osteoporos Int; 2024 May; 35(5):841-849. PubMed ID: 38296866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effects, safety, and predictors of the effectiveness of romosozumab in primary and secondary osteoporosis: An observational study.
    Mineta K; Nishisho T; Okada M; Kamada M; Sairyo K
    Bone; 2024 Sep; 186():117164. PubMed ID: 38871265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients.
    Shimizu T; Arita K; Murota E; Hiratsuka S; Fujita R; Ishizu H; Asano T; Takahashi D; Takahata M; Iwasaki N
    J Bone Miner Metab; 2021 Sep; 39(5):868-875. PubMed ID: 33847831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
    N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.